Product
Nituozumab
1 clinical trial
1 indication
Indication
HNSCCClinical trial
Radiotherapy Combined With Nitozumab and Sinilimab in the Treatment of Locally Advanced Unresectable Platinum Intolerant Head and Neck Squamous Cell Carcinoma： an Open-label Single-arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2026-01-01